Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain.

The three presentations will include:

Phase 1b data from anzu-cel , the Company’s lead PRAME cell therapy, in metastatic cutaneous and uveal melanoma , focusing on predictors of durable responsePhase 1 data from IMA203CD8 PRAME cell therapy across multiple PRAME-positive solid tumors , including durability follow-up at clinically relevant dose levels in gynecologic cancers, supporting the broad applicability of IMA203CD8 across diverse tumor typesPhase 1b data from IMA402, the Company’s PRAME bispecific , at recommended Phase 2 dose (RP2D) range across multiple cancers , supporting continued development in expansion cohorts and combination approaches

Collectively, these presentations highlight the breadth of Immatics' PRAME franchise across two therapeutic modalities and a broad range of solid tumor indications.

Full abstracts will be published on the ESMO website on October 19, 2026, at 00:05 CEST.

Details on Oral and Poster Presentations

Title: Response durability with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy, in advanced melanoma

Presenting Author: Winfried Alsdorf, MD

Presentation Type: Poster presentation

Date / Time: October 24, 2026 / 12:00 – 12:45 CET

Presentation Number: 2128P

Title: Targeting PRAME+ Tumors with IMA203CD8, a PRAME-directed TCR T-cell Therapy: Results from a Phase 1 Study

Presenting Author: Antonia Busse, MD

Presentation Type: Proffered Paper presentation (oral presentation)

Session: Proffered paper: Investigational immunotherapy

Date / Time: October 23, 2026 / 13:30 – 15:00 CET

Presentation Number: 1946O

Title: Initial Results with IMA402 a PRAME-Targeted T-cell Receptor (TCR)-based Bispecific T-cell Engager (TCER) in Advanced Solid Tumors

Presenting Author: Dirk Schadendorf, MD

Presentation Type: Rapid Oral presentation

Session: Rapid oral: Investigational immunotherapy

Date / Time: October 24, 2026 / 08:30 – 10:00 CET

Presentation Number: 1955RO

About PRAME

PRAME is a target expressed in more than 50 cancers. Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and modalities. The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy.

About Immatics

Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.